Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying

California-based TCG Crossover Management added 245,664 shares of Centessa Pharmaceuticals (NASDAQ:CNTA), increasing its position by an estimated $38.1 million in the third quarter, according to an SEC filing released on Friday.According to a filing with the U.S. Securities and Exchange Commission released Friday, TCG Crossover Management bought 245,664 additional shares of Centessa Pharmaceuticals (NASDAQ:CNTA). The fund’s total CNTA position rose to 3.1 million shares following the transaction, with a quarter-end market value of $76.1 million. The transaction accounted for a 0.2% shift in the fund’s $2 billion in reportable U.S. equity AUM.TCG Crossover Management’s CNTA holding now represents 3.7% of its 13F AUM, ranking as the fund’s fifth-largest position out of 40 total holdings.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool